Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$212.79
-1.3%
$208.53
$181.73
$244.81
$375.96B0.326.95 million shs4.71 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$23.79
+0.2%
$24.03
$13.74
$70.43
$5.42B2.4332.29 million shs16.16 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,066.77
+0.2%
$944.65
$623.78
$1,133.95
$1.00T0.483.18 million shs2.98 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$119.75
-2.2%
$116.05
$75.40
$125.14
$295.76B0.1810.90 million shs10.01 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.26
-1.6%
$40.43
$35.12
$81.44
$197.62B0.7721.12 million shs9.29 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.86
-0.2%
$26.84
$23.06
$28.75
$147.39B0.3541.72 million shs29.04 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+3.07%+8.71%-5.44%+17.72%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
0.00%+6.55%-22.57%+53.63%-56.80%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+7.87%+20.54%+2.29%+49.39%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+8.81%+9.58%-1.25%+57.94%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+1.33%+9.02%+16.23%-33.23%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+2.43%-4.03%-4.49%+11.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$212.79
-1.3%
$208.53
$181.73
$244.81
$375.96B0.326.95 million shs4.71 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$23.79
+0.2%
$24.03
$13.74
$70.43
$5.42B2.4332.29 million shs16.16 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,066.77
+0.2%
$944.65
$623.78
$1,133.95
$1.00T0.483.18 million shs2.98 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$119.75
-2.2%
$116.05
$75.40
$125.14
$295.76B0.1810.90 million shs10.01 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.26
-1.6%
$40.43
$35.12
$81.44
$197.62B0.7721.12 million shs9.29 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.86
-0.2%
$26.84
$23.06
$28.75
$147.39B0.3541.72 million shs29.04 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+3.07%+8.71%-5.44%+17.72%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
0.00%+6.55%-22.57%+53.63%-56.80%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+7.87%+20.54%+2.29%+49.39%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+8.81%+9.58%-1.25%+57.94%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+1.33%+9.02%+16.23%-33.23%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+2.43%-4.03%-4.49%+11.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$253.4319.10% Upside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.12
Hold$28.7020.64% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.0015.02% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.187.04% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5648.13% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.6110.64% Upside

Current Analyst Ratings Breakdown

Latest HIMS, NVO, PFE, LLY, MRK, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,133.00 ➝ $1,251.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,119.00
5/26/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Lower Price TargetNeutral$28.00 ➝ $25.00
5/22/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Set Price Target$23.00
5/22/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetHold$18.00 ➝ $23.00
5/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,283.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,350.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$1,300.00 ➝ $1,330.00
5/19/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B)Buy (B-)
5/19/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Lower Price TargetNeutral$30.00 ➝ $28.00
(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B6.15$14.94 per share14.24($3.74) per share-56.90
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B2.31$0.84 per share28.38$1.96 per share12.14
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B15.41$25.18 per share42.37$33.13 per share32.20
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.55$11.17 per share10.72$18.60 per share6.44
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.22$4.62 per share9.59$7.12 per share6.22
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.36$4.39 per share5.89$15.86 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$2.03104.8213.050.745.79%-576.45%13.39%7/30/2026 (Estimated)
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.09N/A48.5546.09-0.56%6.10%1.52%8/10/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1537.9024.121.1634.98%105.77%23.76%8/5/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5533.7312.242.7613.59%27.55%10.73%8/4/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.3912.874.0137.23%63.31%22.19%8/5/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.749.04N/A11.83%19.44%8.41%8/4/2026 (Estimated)

Latest HIMS, NVO, PFE, LLY, MRK, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
4/29/2026Q1 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.923.25%+6.80%340.89%53 Years
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.65%+15.18%24.58%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.84%+5.75%95.77%14 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.95%+21.74%41.08%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.65%-13.20%131.30%16 Years

Latest HIMS, NVO, PFE, LLY, MRK, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.80
0.68
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.18
1.69
1.56
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442227.94 million201.13 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Thinning revenues: inside the $14bn Eliquis patent cliff
If Viking Therapeutics Is Acquired, Here's Who Wins
Arnhold LLC Raises Stock Holdings in Pfizer Inc. $PFE
Swedbank AB Raises Holdings in Pfizer Inc. $PFE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$212.79 -2.91 (-1.35%)
As of 03:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$23.79 +0.04 (+0.17%)
As of 03:58 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,066.77 +1.77 (+0.17%)
As of 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$119.75 -2.66 (-2.17%)
As of 03:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.26 -0.70 (-1.56%)
As of 03:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$25.86 -0.04 (-0.15%)
As of 03:58 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.